Clinical Trial Update: Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating zanubrutinib with R-CHOP for newly diagnosed diffuse large B-cell lymphoma with high-risk factors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• R-CHOP
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Liaoning Cancer Hospital & Institute | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: UNKNOWN